A.P. Pharma announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for APF530 for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013. A.P. Pharma’s NDA for APF530 was resubmitted to the FDA on September 27, 2012.

APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company’s proprietary Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV.

For more information call (650) 366-2626 or visit www.appharma.com.